Although direct molecular interactions between RAC2 and PTTG1 have not been conclusively established, existing evidence indicates that these proteins co-regulate critical cancer-related pathways, including epithelial–mesenchymal transition (EMT), immune evasion, and tumor progression. Here, RAC2 is linked to cancer.